



24 January 2023
EMA/20760/2023

Shortage of Pazenir (paclitaxel) paclitaxel formulated as albumin-bound nanoparticles / 5 mg/ml powder for dispersion for infusion

Indication	<p>Pazenir is used to treat:</p> <ul style="list-style-type: none">• metastatic breast cancer, when the first treatment has stopped working and standard treatment including an anthracycline is not suitable;• metastatic adenocarcinoma of the pancreas, as a first treatment in combination with another cancer medicine, gemcitabine;• and non-small cell lung cancer, as a first treatment in combination with the cancer medicine carboplatin when the patient cannot have surgery or radiotherapy.
Reason for shortage	<p>There has been an increase in demand in Europe for albumin-bound nanoparticle paclitaxel. This is expected to lead to a temporary supply shortage in some EU Member States from January 2023. The shortage is not related to a quality defect of the product or a safety issue.</p>
Member States affected¹	<p>Austria, Bulgaria, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Portugal, Romania, Slovakia, Slovenia and Spain.</p>
Information to healthcare professionals	<ul style="list-style-type: none">• An increase in demand for albumin-bound nanoparticle paclitaxel is expected to lead to a temporary supply shortage of the medicine from January 2023.• The company that markets Pazenir is increasing the production of albumin-bound nanoparticle paclitaxel and working with national authorities to assess how to allocate the medicine across EU Member States.• In the meantime, healthcare professionals should consider alternative treatment options for their patients if Pazenir is not available.• A direct healthcare professional communication (DHPC) will be sent to healthcare professionals in affected Member States and will also be published on the EMA website.• Additional advice, including information on suitable

¹ This information may change. For accurate information about the status of a medicine shortage in a particular Member State the national competent authority should be contacted.



Shortage of Pazenir (paclitaxel) paclitaxel formulated as albumin-bound nanoparticles / 5 mg/ml powder for dispersion for infusion

	alternatives, may be available from the national competent authority .
Information to patients	<ul style="list-style-type: none">• Pazenir contains the cancer medicine paclitaxel attached to the human protein albumin, in the form of tiny particles known as nanoparticles.• An increase in demand for albumin-bound nanoparticle paclitaxel will lead to a temporary supply shortage of the medicine in some EU countries.• Your doctor will prescribe you a treatment alternative if Pazenir is not available.• Additional advice may be available from your national competent authority.
Status	Ongoing